BUFFALO, N.Y., March 31, 2016 /PRNewswire/ — OmniSeq LLC today announced the appointment of biotech industry veteran Mark Gardner as CEO and member of its Board of Directors. His role will be effective in April after he transitions from his executive management post at Thermo Fisher Scientific.

Mr. Gardner brings more than 30 years of senior management experience to OmniSeq. He is a proven business leader who has worked for globally renowned organizations and is very well respected in the life science industry for his successful endeavors in both early stage and well-established businesses in the next-generation sequencing space. He is currently vice president and general manager for Thermo Fisher’s Next Generation Clinical Sequencing business, where he oversees sales, product management, marketing and research and development.

Prior to this role, Mr. Gardner held senior management positions at McKinsey and Company, GE Medical Systems, Invitrogen and Life Technologies. He is a graduate of the United States Naval Academy with distinction. He also holds a master’s degree in national security studies from Georgetown University and an MBA from The Wharton School at the University of Pennsylvania. By adding Mr. Gardner to the executive team and Board of Directors, OmniSeq will leverage his substantial management experience and expertise in oncology-based genomics.

“Mark’s unique ability to turn vision and strategy into exceptional execution and his proven leadership skills are exactly what OmniSeq needs as it enters its next chapter of growth,” said OmniSeq’s Founder, Chairman and Chief Scientific Officer Dr. Carl Morrison. “There is an unmet need in the field of personalized medicine and Mark recognizes that OmniSeq fills that need by providing oncologists and other physicians with clinically actionable information through its proprietary testing platforms and tailored reports so they can formulate treatment options for their patients.”

“I see the potential for OmniSeq’s technology to play a greater role in providing oncologists and other physicians with valuable treatment choices for their patients,” Gardner said.  “Executing OmniSeq’s vision and delivering on its commitment is an incredibly exciting task which I am honored to assume.”

About OmniSeq, LLC
OmniSeq, LLC was established in June 2015 as a for-profit company created from the Center for Personalized Medicine at Roswell Park Cancer Institute (RPCI).  OmniSeq offers a suite of innovative products that support a physician-driven, collaborative approach to genomic diagnostics for cancer. The OmniSeqSM product line provides doctors and institutions with the first-ever fusion of clinical genomics and a comprehensive information technology solution that delivers easy access to actionable insights about a patient’s tumor genetics and available treatment options. Headquartered in Buffalo, OmniSeq offers services throughout the U.S.  For more information, call 1-800-781-1259 or visit www.omniseq.com.